Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2022

View Archived Issues

MRT-2359 shows promise for Myc-driven solid tumors

M-1774 demonstrates potent antitumor activity both as monotherapy and in combination

Post viral infection, resting T-cell subtypes cooperate to drive neuroinflammation

Incyte discloses new GTPase KRAS mutant inhibitors

Cadila Healthcare patents viral nsp3 inhibitors

Asahi Kasei Pharma and Vernalis Group present new IRAK inhibitors

Janssen synthesizes new DHODH inhibitors

Sunshine Lake Pharma patents new GNRHR antagonists

JNJ-78306358, a novel bispecific antibody with HLA-G expression-dependent antitumor activity

Cocrystal Pharma's 3CL protease inhibitors to be studied by NIAID for COVID-19

Discovery of novel orally bioavailable CREB inhibitor

Codexis and seqWell partner to accelerate commercialization of genomics workflow solutions

Novel PAD4 inhibitor JBI-1044 shows strong potency for cancer treatment

CureVac reports preclinical data on bivalent second-generation COVID-19 vaccine

n-Lorem receives funding to support ASO discovery for nano-rare neurodevelopmental diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.